Loading...
XLON
NCYT
Market cap37mUSD
May 28, Last price  
45.75GBP
1D
16.55%
1Q
-3.93%
IPO
-17.73%
Name

Novacyt SA

Chart & Performance

D1W1MN
P/E
—
P/S
279.05
EPS
—
Div Yield, %
—
Shrs. gr., 5y
13.40%
Rev. gr., 5y
-1.31%
Revenues
12m
-44.97%
762,831901,9901,006,2313,539,1246,562,0139,441,22813,275,32112,369,30411,175,527277,204,00095,780,00021,040,00011,579,000
Net income
-28m
L+27.44%
000000000132,423,000-9,728,000-22,201,000-28,292,000
CFO
-25m
L+82.03%
000000000102,976,00015,689,000-13,729,000-24,991,000

Profile

Novacyt S.A., together with its subsidiaries, engages in the development, manufacture, contract design, and commercialization of diagnostic products for cancer and infectious diseases in the United Kingdom, rest of Europe, the United States, the Asia Pacific, the Middle East, and Africa. It operates through Primer Design, Lab21 Products, and IT-IS International. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the areas of infectious diseases. The Lab21 Products segment develops, manufactures, and distributes a range of protein-based infectious disease in-vitro diagnostic device (IVD) products. The IT-IS International segment develops and manufactures PCR devices for the life sciences and food testing industry. It serves hospitals and corporates. The company was incorporated in 2006 and is based in Vélizy-Villacoublay, France.
URL
https://novacyt.com/
IPO date
Oct 12, 2012
Employees
222
Domiciled in
FR
Incorporated in
FR

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
11,579
-44.97%
21,040
-78.03%
Cost of revenue
16,955
30,023
Unusual Expense (Income)
NOPBT
(5,376)
(8,983)
NOPBT Margin
Operating Taxes
(768)
2,148
Tax Rate
NOPAT
(4,608)
(11,131)
Net income
(28,292)
27.44%
(22,201)
128.22%
Dividends
Dividend yield
Proceeds from repurchase of equity
(47)
(13)
BB yield
Debt
Debt current
1,209
609
Long-term debt
26,199
1,135
Deferred revenue
Other long-term liabilities
2,272
145
Net debt
(16,703)
(84,508)
Cash flow
Cash from operating activities
(24,991)
(13,729)
CAPEX
(517)
(416)
Cash from investing activities
(13,935)
(577)
Cash from financing activities
(3,967)
(516)
FCF
(14,275)
(5,939)
Balance
Cash
44,063
86,982
Long term investments
48
(730)
Excess cash
43,532
85,200
Stockholders' equity
33,955
65,498
Invested Capital
69,263
50,729
ROIC
ROCE
EV
Common stock shares outstanding
70,626
70,626
Price
Market cap
EV
EBITDA
4,267
(1,065)
EV/EBITDA
Interest
682
489
Interest/NOPBT